

**TRADEMARK ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST

**CONVEYING PARTY DATA**

Name	Formerly	Execution Date	Entity Type
PR Pharmaceuticals, Inc.		10/11/2005	CORPORATION: DELAWARE

**RECEIVING PARTY DATA**

<b>Name:</b>	KBC Private Equity NV
<b>Street Address:</b>	Havenlaan 12
<b>Internal Address:</b>	1080
<b>City:</b>	Brussels
<b>State/Country:</b>	BELGIUM
<b>Entity Type:</b>	CORPORATION: BELGIUM

<b>Name:</b>	KBC Private Equity Fund Biotech
<b>Street Address:</b>	Havenlaan 12
<b>Internal Address:</b>	1080
<b>City:</b>	Brussels
<b>State/Country:</b>	BELGIUM
<b>Entity Type:</b>	CORPORATION: BELGIUM

<b>Name:</b>	KBC Equity Fund NV - Biotechnology
<b>Street Address:</b>	Havenlaan 12
<b>Internal Address:</b>	1080
<b>City:</b>	Brussels
<b>State/Country:</b>	BELGIUM
<b>Entity Type:</b>	CORPORATION: BELGIUM

<b>Name:</b>	KBC Equity Fund NV - Pharma
<b>Street Address:</b>	Havenlaan 12
<b>Internal Address:</b>	1080
<b>City:</b>	Brussels
<b>State/Country:</b>	BELGIUM

CH \$65.00 2847604

Entity Type: CORPORATION: BELGIUM

Name:	Creafund NV
Street Address:	Kapitein Maenhoutstraat 77B
Internal Address:	9830
City:	Sint-Martens-Laten
State/Country:	BELGIUM
Entity Type:	CORPORATION: BELGIUM

PROPERTY NUMBERS Total: 2

Property Type	Number	Word Mark
Registration Number:	2847604	THERAPHASE
Registration Number:	1284917	PR

CORRESPONDENCE DATA

Fax Number: (415)693-2222  
*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*  
Phone: (415) 693-2136  
Email: trademarks@cooley.com  
Correspondent Name: Barry Graynor  
Address Line 1: 101 California Street  
Address Line 2: 5th Floor  
Address Line 4: San Francisco, CALIFORNIA 94111-5800

ATTORNEY DOCKET NUMBER: 167732-100

DOMESTIC REPRESENTATIVE

Name: Barry Graynor  
Address Line 1: 101 California Street  
Address Line 2: 5th Floor  
Address Line 4: San Francisco, CALIFORNIA 94111-5800

DOMESTIC REPRESENTATIVE

Name: Barry Graynor  
Address Line 1: 101 California Street  
Address Line 2: 5th Floor  
Address Line 4: San Francisco, CALIFORNIA 94111-5800

DOMESTIC REPRESENTATIVE

Name: Barry Graynor  
Address Line 1: 101 California Street

Address Line 2: 5th Floor  
Address Line 4: San Francisco, CALIFORNIA 94111-5800

**DOMESTIC REPRESENTATIVE**

Name: Barry Graynor  
Address Line 1: 101 California Street  
Address Line 2: 5th Floor  
Address Line 4: San Francisco, CALIFORNIA 94111-5800

**DOMESTIC REPRESENTATIVE**

Name: Barry Graynor  
Address Line 1: 101 California Street  
Address Line 2: 5th Floor  
Address Line 4: San Francisco, CALIFORNIA 94111-5800

NAME OF SUBMITTER:	Chris Rhem
Signature:	/CR12991/
Date:	10/11/2005

Total Attachments: 3  
source=PRPharm#page1.tif  
source=PRPharm#page2.tif  
source=PRPharm#page3.tif

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Registrant/Applicant: PR PHARMACEUTICALS, INC., a Delaware corporation  
Trademarks: See Attached Exhibit A

GRANT OF TRADEMARK SECURITY INTEREST

WHEREAS, PR PHARMACEUTICALS, INC., a Delaware corporation, having its principal offices at 1716 Heath Parkway, Fort Collins, CO 80524 (the "Company"), has adopted or used the Trademarks listed on the attached Exhibit A, now registered or in the process of registration in the United States Patent and Trademark Office; and

WHEREAS, the Company has entered into that certain Security Agreement dated as of October 11, 2005 (the "Security Agreement"), by and among the Company, the secured parties listed on Schedule 1 attached hereto and on any addendum to Schedule 1 entered into by the Company, the Collateral Agent (as defined below), and any additional secured parties to reflect any additional purchasers pursuant to Section 2.3(a) of the Purchase Agreement (as defined in the Security Agreement) (each a "Secured Party" and collectively, the "Secured Parties"), and KBC PRIVATE EQUITY N.V., in its capacity as Collateral Agent on behalf of the Secured Parties ("Collateral Agent");

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, the Company hereby:

1. grants a security interest to the Collateral Agent, on behalf of the Secured Parties, in all right, title and interest of the Company pursuant to the Security Agreement, in and to the Trademarks, together with associated goodwill; and
2. authorizes and requests the Commissioner of Patents and Trademarks of the United States of America to note and record the existence of the grant hereby given.


The Company does hereby further acknowledge and affirm that the rights and remedies of the Collateral Agent with respect to the security interest in the Trademarks granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which are hereby incorporated herein by reference as if fully set forth herein.

IN WITNESS WHEREOF, the Company has caused this Grant to be signed by its duly authorized representative as of this 11<sup>th</sup> day of October 2005.

PR PHARMACEUTICALS, INC.

By: 

Its: President

By: 

KURTIS W. NESTMAN  
CHIEF FINANCIAL OFFICER

**SCHEDULE 1  
TO GRANT OF TRADEMARK SECURITY INTEREST**

**SECURED PARTIES:**

KBC Private Equity NV  
KBC Private Equity Fund Biotech  
KBC Equity Fund NV – Biotechnology  
KBC Equity Fund NV – Pharma  
Creafund NV

**COLLATERAL AGENT:**

KBC Private Equity NV

Address of Collateral Agent:           Havenlaan 12  
  1080 Brussels  
  Belgium

**Exhibit A**

**U.S. TRADEMARKS**

<b>MARK</b>	<b>REGISTRATION NO.</b>	<b>REGISTRATION DATE</b>
THERAPHASE	2,847,604	06/01/2004
PR	1,284,917	07/10/1984